KBC Securities - BIOTALYS NV (BTLS) Biotalys FIRST LOOK : FY23 results, ready at the starting blocks

Report

KBC Securities

Guy Sips ...

Thomas Vranken

Biotalys FIRST LOOK : FY23 results, ready at the starting blocks

No major surprises out of Biotalys' FY23 update as the company continues its work with the EPA for regulatory approval of Evoca. Meanwhile, new management fine-tuned the technology platform and restructured the pipeline with BioFun-6 now coming forward as the next candidate for field trials. Cash landed higher than expected at € 21.6m, implying runway until April 2025. We maintain our conviction in Biotalys' technology while we await a regulatory decision, and reiterate our € 6.0 TP and Buy rating.

22/02/2024 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

: AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

May 2, 2024 May 2, 2024 1 EN

KBC Securities

Morning Notes : CPINV BB, OPTI BB, BTLS BB, ONWD BB

: CPINV BB, OPTI BB, BTLS BB, ONWD BB

March 18, 2024 March 18, 2024 1 EN

KBC Securities

Biotalys Manufacturing/commercialisation partnership for Evoca NG with Novonesis

We welcome Biotalys and Novonesis announced a manufacturing and commercialisation partnership for Evoca NG. Leveraging Novonesis' world leading fermentation capabilities can not only add value to Biotalys' very promising Agrobody technology but (as Novonesis is one of the leaders in the field of biosolutions) this can as well be seen as an important step forward for Biotalys as they lay the foundation for future commercial launches from its Agrobody 2.0 technology platform. We reiterate our Buy rating and € 6.0 Target Price.

March 18, 2024 March 18, 2024 1 EN

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

In a new note focusing on Wind Energy, we aim to provide a broad insight into the value chain, the risks associated with it and the positioning of the companies in the sector. The current market environment presents both opportunities and challenges for wind energy companies. The sector has faced multiple headwinds in the past, such as inflation, rising interest rates and supply chain issues, which resulted in a substantial decline in the stock prices of wind companies. However, there's a lot of upside potential driven by the growth in the sector. This is mainly caused by the Net Zero Energy...

9h / 3m 9h / 3m 1 EN

Guy Sips

Guy Sips

Jensen-Group FIRST LOOK : A good start to 2024

Jensen-Group 1Q24 revenues were up y/y 11.6% to € 109.1m. The 1Q24 order intake increased y/y 34.4% to €114.9m. As a result Jensen-Group called this “a good start to 2024”. 1Q24 EBIT came in at € 11.2m (€ 11.4m in 1Q23) resulting in 10.3% 1Q24 EBIT-margin (11.7% in 1Q23). 1Q24 net result amounted to € 11.1m (€ 1.15 EPS). We maintain for the moment our Accumulate rating and € 40 Target Price as these numbers are ahead of our FY24 forecasts of 8.8% FY24E sales growth and 9.5% FY24E EBIT-margin. We will update our model after visiting this week a Jensen-Group client.

9h / 6m 9h / 6m 1 EN

Jacob Mekhael

Jacob Mekhael

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Autolus reported uneventful 1Q24 results, with a cash position of $758.5m (FY23: $ 239.6m), sufficient to fund the company into the first pivotal data from obe-cel (CD19 CAR-T) in autoimmune disease (we expect this to come in 2027/2028). The company reiterated pipeline timelines, with the next key event being additional analysis and longer follow up from the phase 2 (FELIX) trial of obe-cel in r/r adult ALL, expected at ASCO in June 2024, which will provide more insight into long term durability. We reiterate our $ 11 TP and BUY rating. Autolus is one of our life sciences top picks.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Biotalys FIRST LOOK : FY23 results, ready at the starting blocks

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

Morning Notes : CPINV BB, OPTI BB, BTLS BB, ONWD BB

Biotalys Manufacturing/commercialisation partnership for Evoca NG with Novonesis

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

Jensen-Group FIRST LOOK : A good start to 2024

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe